JP2006518376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006518376A5 JP2006518376A5 JP2006502807A JP2006502807A JP2006518376A5 JP 2006518376 A5 JP2006518376 A5 JP 2006518376A5 JP 2006502807 A JP2006502807 A JP 2006502807A JP 2006502807 A JP2006502807 A JP 2006502807A JP 2006518376 A5 JP2006518376 A5 JP 2006518376A5
- Authority
- JP
- Japan
- Prior art keywords
- present
- disease
- compound
- invention further
- malignant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300480A SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Novel compounds |
| PCT/SE2004/000227 WO2004074224A1 (en) | 2003-02-21 | 2004-02-19 | Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006518376A JP2006518376A (ja) | 2006-08-10 |
| JP2006518376A5 true JP2006518376A5 (enExample) | 2007-03-15 |
Family
ID=20290476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502807A Withdrawn JP2006518376A (ja) | 2003-02-21 | 2004-02-19 | アダマンタン誘導体、その製造方法、それらを含む医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7227038B2 (enExample) |
| EP (1) | EP1599432A1 (enExample) |
| JP (1) | JP2006518376A (enExample) |
| KR (1) | KR20050101559A (enExample) |
| CN (1) | CN100378047C (enExample) |
| AU (1) | AU2004213356B2 (enExample) |
| BR (1) | BRPI0407734A (enExample) |
| CA (1) | CA2515434A1 (enExample) |
| CO (1) | CO5580815A2 (enExample) |
| IL (1) | IL169818A0 (enExample) |
| IS (1) | IS8024A (enExample) |
| MX (1) | MXPA05008690A (enExample) |
| NO (1) | NO20054329L (enExample) |
| PL (1) | PL378574A1 (enExample) |
| RU (1) | RU2005123802A (enExample) |
| SE (1) | SE0300480D0 (enExample) |
| WO (1) | WO2004074224A1 (enExample) |
| ZA (1) | ZA200506579B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| CA2526883A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha. |
| US20070010497A1 (en) * | 2003-05-29 | 2007-01-11 | Nigel Boughton-Smith | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| WO2004105796A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| US8916546B2 (en) | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| CA2549869C (en) | 2003-12-18 | 2015-05-05 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
| GB0403864D0 (en) | 2004-02-20 | 2004-03-24 | Ucl Ventures | Modulator |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
| WO2007008157A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 2 |
| WO2007008155A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 1 |
| ES2569428T3 (es) | 2006-07-13 | 2016-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina como MTKI |
| TW200819416A (en) * | 2006-09-05 | 2008-05-01 | Astrazeneca Ab | Novel process 470 |
| AU2008281849B2 (en) | 2007-07-27 | 2013-11-28 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| ES2357682T3 (es) | 2008-03-25 | 2011-04-28 | Affectis Pharmaceuticals Ag | Antagonistas de p2x7r novedosos y su utilización. |
| KR20100053150A (ko) * | 2008-11-12 | 2010-05-20 | 한국생명공학연구원 | 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 ｄｎａ 메틸트렌스퍼레이즈 억제용 약학적 조성물 |
| DK2243772T3 (da) | 2009-04-14 | 2012-02-13 | Affectis Pharmaceuticals Ag | Hidtil ukendte P2X7R-antagonister og deres anvendelse |
| CN102858741A (zh) | 2010-05-14 | 2013-01-02 | 阿费克蒂斯制药股份公司 | 制备p2x7r拮抗剂的新方法 |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| ES2574840T3 (es) | 2011-07-22 | 2016-06-22 | Actelion Pharmaceuticals Ltd. | Derivados de amidas heterocíclicas como antagonistas de receptores p2x7 |
| KR102033190B1 (ko) | 2012-01-20 | 2019-10-16 | 이도르시아 파마슈티컬스 리미티드 | Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| EP2916818B1 (en) | 2012-11-09 | 2017-02-01 | Scidose LLC | Enema composition for treatment of ulcerative colitis having long term stability |
| EA029644B1 (ru) | 2012-12-12 | 2018-04-30 | Идорсиа Фармасьютиклз Лтд | Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов |
| CA2891499C (en) | 2012-12-18 | 2021-07-06 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| KR102220847B1 (ko) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| CA2896790C (en) | 2013-01-22 | 2022-05-10 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3352912A (en) | 1963-07-24 | 1967-11-14 | Du Pont | Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes |
| US3471491A (en) | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| GB1274652A (en) | 1968-08-27 | 1972-05-17 | Lilly Industries Ltd | Adamantanyl-alkylamine derivatives and their preparation |
| IL53441A0 (en) | 1977-11-22 | 1978-01-31 | Teva Pharma | Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them |
| US4349552A (en) | 1978-10-30 | 1982-09-14 | Fujisawa Pharmaceutical Company, Ltd. | 5-Fluorouracil derivatives, and their pharmaceutical compositions |
| US4751292A (en) | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| HU222178B1 (hu) | 1993-08-10 | 2003-04-28 | James Black Foundation Ltd. | Gasztrin és CCK-receptor ligandumok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények |
| FR2761358B1 (fr) | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ZA988967B (en) | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| RU2254333C2 (ru) * | 1999-04-09 | 2005-06-20 | Астразенека Аб | Производные адамантана, способ их получения, фармацевтическая композиция на их основе и способы лечения |
| SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| ES2333412T3 (es) | 2001-05-25 | 2010-02-22 | Bristol-Myers Squibb Company | Derivados de hidantoina como inhibidores de metaloproteinasas de matriz. |
| KR100908468B1 (ko) | 2001-07-02 | 2009-07-21 | 엔.브이.오가논 | 테트라히드로퀴놀린 유도체 |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300445D0 (sv) | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
| WO2004105796A1 (en) | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| CA2526883A1 (en) | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha. |
| US20070010497A1 (en) | 2003-05-29 | 2007-01-11 | Nigel Boughton-Smith | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
-
2003
- 2003-02-21 SE SE0300480A patent/SE0300480D0/xx unknown
-
2004
- 2004-02-19 WO PCT/SE2004/000227 patent/WO2004074224A1/en not_active Ceased
- 2004-02-19 CA CA002515434A patent/CA2515434A1/en not_active Abandoned
- 2004-02-19 JP JP2006502807A patent/JP2006518376A/ja not_active Withdrawn
- 2004-02-19 MX MXPA05008690A patent/MXPA05008690A/es unknown
- 2004-02-19 BR BRPI0407734-2A patent/BRPI0407734A/pt not_active IP Right Cessation
- 2004-02-19 US US10/546,131 patent/US7227038B2/en not_active Expired - Fee Related
- 2004-02-19 CN CNB2004800047676A patent/CN100378047C/zh not_active Expired - Fee Related
- 2004-02-19 RU RU2005123802/04A patent/RU2005123802A/ru not_active Application Discontinuation
- 2004-02-19 EP EP04712798A patent/EP1599432A1/en not_active Withdrawn
- 2004-02-19 PL PL378574A patent/PL378574A1/pl not_active Application Discontinuation
- 2004-02-19 KR KR1020057015302A patent/KR20050101559A/ko not_active Withdrawn
- 2004-02-19 AU AU2004213356A patent/AU2004213356B2/en not_active Ceased
-
2005
- 2005-07-21 IL IL169818A patent/IL169818A0/en unknown
- 2005-08-02 CO CO05076011A patent/CO5580815A2/es not_active Application Discontinuation
- 2005-08-17 ZA ZA200506579A patent/ZA200506579B/en unknown
- 2005-09-14 IS IS8024A patent/IS8024A/is unknown
- 2005-09-20 NO NO20054329A patent/NO20054329L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006518376A5 (enExample) | ||
| Jacob et al. | Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity | |
| RU2008129600A (ru) | Комбинация и фармацевтический препарат для лечения воспалительных заболеваний | |
| PE20060489A1 (es) | Formulacion farmaceutica que comprende un antibiotico, un triazol y un corticosteroide | |
| RU2014113906A (ru) | Терапевтическое применение эктоина | |
| NO20070994L (no) | N-hydroksamid derivater og anvendelse derav | |
| Gulliver et al. | Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations | |
| JP2014526448A5 (enExample) | ||
| JP2019503997A5 (enExample) | ||
| JP2021500403A5 (enExample) | ||
| JP2013525338A5 (enExample) | ||
| HUP9903707A2 (hu) | 17Béta-karboxi-,-tio-karboxi-vagy -amido-androsztánszármazékok laktonszármazékai, előállításuk, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| JP2005509642A (ja) | 新規の抗炎症性アンドロスタン誘導体 | |
| JP2019528316A5 (enExample) | ||
| RU2010108640A (ru) | Новая комбинация терапевтических агентов | |
| JP2017197569A5 (enExample) | ||
| JP2015506983A5 (enExample) | ||
| JP2007530580A5 (enExample) | ||
| JP2007533683A5 (enExample) | ||
| RU2006137717A (ru) | [4-(-аминометил-2-фторфенил)-пеперидин-1-ил]-(4-бром-3-метид-5-пропокситиофен-2-ил)-метанон гидрохлорид как ингибитор триптазы тучных клеток | |
| JP2007506681A5 (enExample) | ||
| MX2018014425A (es) | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. | |
| RU2015145135A (ru) | Лечение воспалительных расстройств | |
| PE20040326A1 (es) | Medicamento que contiene esteroides y un nuevo anticolinergico | |
| Beeh et al. | Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases |